Medicine and Dentistry
Uterine Cancer
100%
Neoplasm
69%
Gynecological Oncology
54%
Cancer
44%
Ovarian Cancer
44%
Diseases
43%
Malignant Neoplasm
41%
Overall Survival
37%
Cervical Cancer
35%
Endometrium Carcinoma
34%
Oncology
33%
Recurrent Disease
25%
Pelvis
22%
Microsatellite Instability
20%
Radiation Therapy
19%
Progression Free Survival
18%
Metastatic Carcinoma
16%
Female Genital Tract Cancer
15%
Carcinoma
15%
Krukenberg Tumor
15%
DNA Mismatch Repair
14%
Paclitaxel
14%
Methylation
12%
Positron Emission Tomography
12%
Carcinosarcoma
11%
Cell Line
10%
Hereditary Nonpolyposis Colorectal Cancer
10%
Hazard Ratio
10%
Adjuvant Therapy
10%
Lymph Node
10%
Body Mass Index
9%
Brachytherapy
9%
Cisplatin
9%
Promoter Region
8%
Fallopian Tube
8%
Disease Free Survival
8%
Cancer Cell
7%
Prognostic Factor
7%
Surgery
7%
Tumor Necrosis Factor
7%
Cervix
7%
Recurrent Ovarian Cancer
7%
Uterine Cervix Carcinoma
7%
Lymph Node Metastasis
7%
Adenocarcinoma
7%
Intensity Modulated Radiation Therapy
7%
Oncologist
7%
Vulva
7%
Vulvar Cancer
7%
CA-125
6%
Keyphrases
Endometrial Cancer
86%
Tumor
49%
Overall Survival
35%
Gynecologic Oncology Group
33%
Ovarian Cancer
32%
Cervical Cancer
31%
NRG Oncology
31%
Whole Genome
30%
Endometrial Carcinoma
30%
Pan-cancer Analysis
26%
Gynecologic Oncology
24%
Chemotherapy
23%
Microsatellite Instability-high (MSI-H)
22%
Group Studies
21%
Cervical Carcinoma
16%
Confidence Interval
16%
Cisplatin
14%
Progression-free Survival
14%
Endometrioid
13%
Gynecologic Malignancies
13%
Gynecological Cancer
13%
Oncology Patients
13%
Paclitaxel
12%
Human Cancer
11%
Hazard Ratio
11%
Endometrioid Endometrial Cancer
11%
Radiation Therapy
10%
Adjuvant Therapy
10%
DNA Mismatch Repair
10%
Advanced Ovarian Cancer
10%
Cancer Patients
9%
Brachytherapy
9%
Uterine Serous Carcinoma
9%
Bevacizumab
9%
In Cancer
9%
Disease-free Survival
8%
Ovarian Cancer Patients
8%
MLH1 Methylation
8%
Malignancy
8%
MLH1
8%
Primary Peritoneal Cancer
8%
Prognostic Factors
8%
Fallopian Tube
8%
Vulvar Cancer
7%
Gynecologic Oncologist
7%
Body Mass Index
7%
Tumor Necrosis Factor-α
7%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
7%
Defective DNA
7%
Carboplatin
7%